Table 3 Analysis of Risk Factors Affecting the Development of Nephrotoxicity
From: Nephrotoxicity caused by colistin use in ICU: a single centre experience
Variables | Univariate | Multivariate | ||
|---|---|---|---|---|
OR (95% CI) | p-value | OR (95% CI) | p-value | |
Age | 1.04 (1.02–1.07) | 0.001 | 1.04 (1.01–1.07) | 0.070 |
Gender | ||||
Female | Reference | – | ||
Male | 0.98 (0.46–2.11) | 0.958 | ||
CCI | 1.28 (1.08–1.52) | 0.004 | 1.08 (0.85–1.37) | 0.553 |
APACHE II score | 1.05 (1.02–1.09) | 0.003 | 1.02 (0.98–1.07) | 0.277 |
Diagnosis ICU admission | ||||
Pneumonia | 0.90 (0.28–2.94) | 0.877 | ||
Bloodstream infection | 1.50 (0.43–5.16) | 0.523 | ||
Urinary tract infection | 0.34 (0.04–2.95) | 0.325 | ||
Soft tissue infection | 5.47 (0.56–53.96) | 0.146 | ||
Nephrotoxic agent | ||||
Concomitant vancomycin | 2.26 (1.12–4.54) | 0.023 | 2.05 (0.90–4.66) | 0.087 |
Concomitant aminoglycoside | 0.58 (0.20–1.72) | 0.328 | ||
Concomitant amphotericin | 1.17 (0.19–7.21) | 0.868 | ||
Vasopressors using | 3.43 (1.70–6.91) | < 0.001 | 2.80 (1.29–6.10) | 0.010 |
Basal creatinine level | 4.81 (1.22–18.99) | 0.025 | 2.67 (0.58–12.44) | 0.209 |
Duration of colistin treatment | 1.06 (1.01–1.11) | 0.046 | 1.04 (0.98–1.12) | 0.202 |